Within high-grade gliomas, the precise identities and functional roles of stem-like cells remain unclear. In the normal neurogenic niche, ID (Inhibitor of DNA-binding) genes maintain self-renewal and multipotency of adult neural stem cells. Using PDGF-and KRAS-driven murine models of gliomagenesis, we show that high Id1 expression (Id1 high ) identifies tumor cells with high self-renewal capacity, while low Id1 expression (Id1 low ) identifies tumor cells with proliferative potential but limited self-renewal capacity. Surprisingly, Id1 low cells generate tumors more rapidly and with higher penetrance than Id1 high cells. Further, eliminating tumor cell self-renewal through deletion of Id1 has modest effects on animal survival, while knockdown of Olig2 within Id1 low cells has a significant survival benefit, underscoring the importance of non-self-renewing lineages in disease progression.
INTRODUCTION
High-grade gliomas (WHO Grade III, IV astrocytomas) are among the most lethal types of solid tumors, with significant cellular and genetic heterogeneity complicating treatment efforts (Terzis et al., 2006) . Since the discovery of glioma cells with properties reminiscent of neural stem cells, including the capacity to selfrenew, there has been a great deal of interest in elucidating their contributions to tumorigenesis. Self-renewal in normal and tumor stem cells occurs when a cell divides to produce at least one daughter cell with the same developmental potential as itself, thus maintaining multipotency (He et al., 2009) . This is in contrast to proliferation, which refers to cell divisions regardless of developmental potential (He et al., 2009) . Within the subventricular zone (SVZ), normal adult neural stem cells (also referred to as ''type B cells'') are rare, slow-cycling and self-renewing cells that give rise to more rapid cycling transit amplifying cells (''type C cells''), which then give rise to more differentiated neuroblasts (''type A cells'') (Doetsch et al., 1997) . Glioma stem cells, likened to type B cells, are defined by their capacity to (1) selfrenew in vitro, (2) transplant tumors in vivo, and (3) generate tumors that recapitulate the heterogeneity of the parental tumors (Stiles and Rowitch, 2008) . The degree to which glioma stem cells resemble neural stem cells, and the degree to which the normal lineage hierarchy is maintained in brain tumors remain unanswered questions.
The cancer stem cell hypothesis predicts that stem cells are responsible for tumor initiation and preferentially drive tumor growth, and indeed, many studies use the term ''glioma-initiating cell'' (GIC) interchangeably with ''glioma-stem cell'' (GSC). However, whether stem-like cells are uniquely qualified in their ability to transplant disease, or whether other, more differentiated,
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High-grade gliomas are typified by poor therapeutic response and rapid lethality. Using two mouse models of gliomagenesis, we identify and isolate two distinct stem-and progenitor-like tumor cell populations using a single marker, Id1. Id1 non-self-renewing lineages possess this capacity, remains controversial (Alcantara Llaguno et al., 2009; Chow et al., 2011; Lindberg et al., 2009; Prestegarden and Enger, 2010; Stiles and Rowitch, 2008) . In other types of brain tumors, including medulloblastoma (Yang et al., 2008) and oligodendroglioma (Persson et al., 2010) , cell lineages that express progenitor markers but are incapable of self-renewal in vitro have been shown to transplant disease. Further, oligodendrocyte precursor cells (OPCs) were recently identified as likely cells-of-origin in a p53/Nf1 mouse model of gliomagenesis, as lineage-analysis revealed this population to have the most dramatic growth expansion prior to malignancy . Adding to the complexity, it has been hypothesized that more differentiated cells may dedifferentiate and acquire a stem cell phenotype during the course of tumorigenesis (Kang et al., 2006) . How frequently this occurs in vivo and whether the acquisition of selfrenewal and ''stemness'' is a requisite for tumorigenic potential requires further investigation.
Critical to the analysis of high-grade gliomas is the identification of markers to definitively isolate and functionally characterize the distinct lineages. CD133 (Prominin-1) is the most common antigen used to identify glioma stem cells, but studies have shown that both CD133 + and CD133 -cells can self-renew and generate histologically distinct tumors (Beier et al., 2007; Chen et al., 2010; Clé ment et al., 2009; Wang et al., 2008) , arguing against CD133 as a specific marker of glioma stem cells. Other studies have used the side population (SP) to define the stem-cell fraction, although this also identifies a heterogeneous population of both self-renewing and non self-renewing lineages (Broadley et al., 2011) . The ID (Inhibitor of DNA-binding) genes are dominant negative regulators of basic helix-loop-helix transcription factors (Perk et al., 2005) with established roles in embryonic stem cell self-renewal (Romero-Lanman et al., 2011; Ying et al., 2003) . Following development, Id1 continues to regulate self-renewal and differentiation in multiple somatic stem cell populations, including adult neural stem cells. High levels of Id1 identify type B adult neural stem cells within neurogenic niches, and Id1 and Id3 are required to maintain the selfrenewal capacity of this cell population (Nam and Benezra, 2009) . During lineage commitment, Id1 protein levels decrease as progenitor markers become more highly expressed (Nam and Benezra, 2009) . While Id1 expression is low to absent in nonneurogenic regions of the normal adult brain, Id1 expression is upregulated in multiple subtypes of human and mouse gliomas (Anido et al., 2010; Vandeputte et al., 2002) . Because high levels of Id1 identify self-renewing type B cells in the normal neurogenic niche, we hypothesized that high levels of Id1 could similarly identify glioma cells with a stem-cell phenotype. Large-scale sequencing projects have identified alterations that frequently occur in human high-grade gliomas, including PDGFRA amplification (13%), alterations in RTK/RAS/PI(3)K signaling (88%) and CDKN2A/Arf homozygous deletion or mutation (49%) (Network, 2008) . This has led to the generation of subclasses based upon specific genomic and proteomic signatures (Brennan et al., 2009; Huse et al., 2011; Network, 2008) . Although studies differ with regard to subclass identity and nomenclature, broadly speaking, tumors with aberrant PDGFR signaling have been grouped in the Proneural subclass, and tumors with mutation and/or deletion of NF1 have been grouped in the Mesenchymal subclass. The PDGFR/Proneural subclass has a well-established RCAS/tva-based mouse model, where adult Nestin-tva;Arf À/À mice are stereotaxically injected with RCAS-PDGFB into the SVZ, generating gliomas with near complete penetrance (Hambardzumyan et al., , 2011 . Tumors can also be initiated using constitutively active mutant KRAS, as KRAS has been shown to cooperate with tumor suppressor loss to generate gliomas (Uhrbom and Holland, 2001; Uhrbom et al., 2005) . Tumors driven by either PDGF or KRAS show a histopathology that closely mimics human tumors, as well as high-grade features, including pseudopalisading necrosis and microvascular proliferation (Hambardzumyan et al., , 2011 Uhrbom and Holland, 2001; Uhrbom et al., 2005) .
Here, we test a central tenet of the cancer stem cell hypothesis, that self-renewal capacity is required for disease transplantation and is a key predictor of tumor growth potential, in PDGF-and KRAS-driven murine glioma models. Figure 1C ). Post-sort analysis was used to confirm the absence of VenusYFP signal in the Id1 low fraction ( Figure S1C) and Id1 high cells were, on average, 0.35% of the total sorted population, including stromal cells ( Figure 1C ). Immunostaining ( Figure 1D ) and RT-PCR ( Figure 1E) Figure 1F ). In contrast, multiple progenitor-associated markers, including Olig2, Mash1, NG2, and Id2 were more highly expressed in Id1 low cells compared to Id1 high cells ( Figure 1F ).
RESULTS

PDGF-and KRAS-Driven
Olig2 is known to regulate proliferation in neural progenitors (Ligon et al., 2007; Sun et al., 2011) and is expressed in multiple lineages, including type C cells in the normal neurogenic niche Error bars represent mean ± SD. See also Figure S1 .
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Self-Renewal Is Not Essential for Glioma Growth and mature oligodendrocytes (Menn et al., 2006) . Olig2 is also expressed in all subtypes of malignant glioma (Ligon et al., 2004) , leading us to more closely examine Olig2 expression in our model. Within PDGF-driven tumors, we observed high levels of Olig2 expression ( Figure 1G) , consistent with what is observed in human gliomas (Figures S1D and S1E) including those from the PDGFR subclass (Verhaak et al., 2010) . By IHC, 5.2% of tumor cells had detectable levels of Id1 expression and 84.6% of cells had detectable levels of Olig2 expression ( Figure 1H ). Sorted Id1 high cells make up a subset of the total Id1-expressing population, as Id1 is expressed in varying levels in both tumor cells and stromal cells. Importantly, Olig2 and Id1 showed a largely mutually exclusive expression pattern ( Figure 1I ). Of Id1-expressing tumor cells, only 6.1% showed some level of Olig2 expression ( Figure S1F ). In the normal neurogenic niche, Id1 levels decrease and progenitor markers increase as cells transition from a type B cell to a type C cell phenotype (Nam and Benezra, 2009) , and this population overlap within tumors may reflect a similar phenomenon. Importantly, we did not detect Olig2 protein expression in the sorted Id1 high population, and found significant Olig2 protein expression in the sorted Id1 low population ( Figure 1J ). In order to test the generality of our results, we examined tumors driven by RCAS mutant KRAS using Nestin-tva; Arf Figures 1Q and 1R) . Coimmunostaining for Id1 and Olig2 again revealed a largely mutually exclusive expression pattern ( Figure 1S ). Importantly, we did not detect Olig2 protein expression in the sorted Id1 high cells, and found significant Olig2 protein expression in the sorted Id1 low cells ( Figure 1T ). Thus, in both PDGF-and KRAS-driven tumors, sorted Id1 high cells were characterized by high levels of the neural stem cell marker Id1, and an absence of common progenitor-associated markers. While Id1 low cells represented heterogeneous tumor bulk, they were characterized by high levels of Olig2 and other progenitor-associated markers.
We further characterized the expression of Id1 and several lineage markers using human glioma tissue microarrays (TMAs). Here, we found that a subset of Id1-expressing cells also expressed the putative stem-cell marker CD133, although we observed both CD133 + /Id1 -and CD133 -/Id1 + cells (Figure S1G) . While Id1 and Olig2 showed a largely exclusive expression pattern in the PDGF-and KRAS-driven murine models, we identified two distinct groups from the human TMAs: one group showed a largely exclusive expression pattern between Id1 and Olig2, while the other group showed a high-degree of overlap between the two proteins ( Figures  S1D and S1E) . We speculate that differences may exist in the Id1/Olig2 lineage relationship, and expression of stem and progenitor cells generally, within distinct subtypes of high-grade gliomas. Figure 2B ). By contrast, from Id1 low primary tumorspheres, 0.33% of single cells formed secondary tumorspheres, of which 0.625% of single cells formed tertiary tumorspheres, with no generation of tumorspheres over additional passages ( Figure 2B ). Id1 high cells generated tumorspheres that were marginally larger than those generated from Id1 low cells ( Figure 2C ). Similar results were observed in KRASdriven tumors, where Id1 high cells showed a 7.5-fold enhancement in primary tumorsphere formation compared to Id1 low cells ( Figure S2B ; 10 cells/ml). From Id1 high primary tumorspheres, 7.67% of cells formed secondary tumorspheres, 1.85% of cells formed tertiary tumorspheres, and 0.267% of cells formed quaternary tumorspheres (plated 0.5 cells/ml; Figure S2C ). By contrast, we were unable to generate secondary tumorspheres (E) Representative images of tumorspheres generated from Id1 high cells that were differentiated and stained for GFAP, Tuj1, and O4. Scale bars = 100 mm for main images, 50 mm for insets. Cells were counterstained with DAPI in fluorescent images.
(F) Number of adherent colonies formed after 7 days in vitro from Id1 low cells (n = 14) compared to Id1 high cells (n = 24) (0.5 cells/ml; *p = 5.29 3 10 À7 ).
(G) Diameter of adherent colonies measured after 3 days (p = 0.38; n = 17), 5 days (p = 0.04; n = 27) and 7 days (*p = 6.39 3 10 À5 ; n = 14) from Id1 low cells 
Self-Renewal Is Not Essential for Glioma Growth from the Id1 low primary tumorspheres at this plating density ( Figure S2C ). Id1 low secondary tumorspheres, as well as Id1 high secondary, tertiary, quaternary, and quinary tumorspheres from the PDGFdriven model were plated under conditions to favor differentiation, and the resultant progeny were quantified. While undifferentiated tumorspheres showed low to absent expression of GFAP, O4, and Tuj1 ( Figures S2D and S2E ), individual Id1 high secondary tumorspheres primarily generated GFAP-expressing astrocytes upon differentiation, with less frequent but consistent generation of O4-expressing oligodendrocytes and Tuj1-expressing neurons (Figures 2D and 2E ; Figure S2F ). Essentially all individual Id1 high tumorspheres showed similar percentages of cells expressing these markers. We also observed similar proportions of GFAP-, O4-, and Tuj1-expressing cells from Id1 high tumorspheres at tertiary, quaternary, and quinary passages (Figure 2D ; Figure S2F ), consistent with these populations undergoing self-renewal events, rather than physical events such as in vitro fusion. The fact that the Id1 high population primarily differentiated into GFAP-expressing cells is also consistent with studies showing a role for Id1 in restraining neural differentiation (Ying et al., 2003) . Id1 low secondary tumorspheres, by contrast, showed a high degree of variability with regards to their differentiation potential: 37.5% primarily generated GFAP-expressing cells, 43.75% primarily generated Tuj1-expressing cells, and 18.75% generated roughly equal numbers of GFAP-and Tuj1-expressing cells (n = 16; Figure S2G ). also plated at clonal density (0.5 cells/ml) as adherent monolayers using the same mitogenic conditions as in the nonadherent tumorsphere assays. Id1 high cells generated colonies more frequently than Id1 low cells ( Figure 2F ), and generated colonies that were marginally larger than those generated from Id1 low cells ( Figure 2G ), paralleling our tumorsphere data (Figures 2A-2C ). We did not observe significant differences in expression of cleaved caspase-3 between colonies generated from Id1 low and Id1 high cells (data not shown), nor did we observe differences in H3P expression after 5 days in vitro ( Figures 2H and 2I Figure 3A ). We were unable to generate tumors with 1.0 3 10 3 cells from either Id1 low or Id1 high cells when they were plated in vitro prior to transplantation (data not shown). Plating cells in vitro also led to changes in Id1 and Olig2 expression ( Figures S3A-S3C Figure 3C ), while 1 of 19 mice (5.3%) injected with 1.0 3 10 3 Id1 high cells developed a low-grade tumor with a survival of 119 days ( Figure 3C ). Therefore, in both PDGF-and KRAS-driven tumors, Id1 low cells generated tumors more quickly and with higher penetrance than Id1 high cells. Figure 4A ). Immunostaining for Id1 revealed that Id1 expression was restricted to GFP expressing cells ( Figure 4B ). We did not observe Id1-expressing/ GFP-nonexpressing cells ( Figure 4C ), indicating that the Id1 expressing cells were in fact host-derived. In contrast to Id1, immunostaining for Olig2 did not colocalize with GFP, indicating that the Olig2 expressing cells were coming from the initiating cell population (Figures 4D and 4E ). We also observed recruitment using cells isolated from the KRAS-driven model (Figure S4A ). These data are consistent with studies in other model systems showing that cells recruited from the normal brain parenchyma can contribute to glioma heterogeneity (Assanah et al., 2006) . To determine whether Id1 expression in the recruited population was important for tumor growth, we injected 1.0 3 10 3 Id1 low cells from PDGF-driven tumors into the cortex of Id1 À/À mice. These mice also developed tumors ( Figure S4B ), Figure 5B ; 1 cell/well). Id1 +/+ Id3 +/+ tumorspheres primarily differentiated into GFAP-expressing cells, with less frequent but consistent generation of O4-and Tuj1-expressing cells ( Figures  5C and 5D ). We observed similar proportions of GFAP-, O4-, and Tuj1-expressing cells from secondary and tertiary tumorspheres ( Figures 5C and 5D) , and a pattern of differentiation closely paralleling that of Id1 high tumorspheres ( Figures 2D and 2E ). in vitro, these differences were not statistically significant (Figure 5F ). Thus, both cell populations were capable of proliferation in vitro.
Cells from
The reduction in self-renewal capacity with Id loss mirrors the effects of Id loss in normal adult neural stem cells (Nam and Benezra, 2009 ). However, we observed only modest effects of Id loss on tumor-free survival ( Figure 5G Scale bars = 100 mm for main images, 50 mm for insets. See also Figure S3 .
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Self-Renewal Is Not Essential for Glioma Growth 34 days ( Figure S5 ). In normal adult neural stem cells, Id1 and Id3 show redundancy of function at the level of self-renewal (Nam and Benezra, 2009 mice injected with RCAS-PDGFB and RCAS-Cre had a median survival no different from control animals (28 days; Figure S5 ). Id1 low tumor cells showed significant growth potential in vivo (Figure 3) , and we hypothesized that inhibiting the growth of the Id1 low population might confer a more significant survival benefit. As Olig2 is a known mediator of glioma growth in cell line models, we inserted an H1 promoter driving Olig2 shRNA downstream of PDGFB in the RCAS vector ( Figures S6A  and S6B ). Using RCAS-PDGFB;Olig2-shRNA or RCAS-PDGFB; shRNA-Control constructs to initiate tumors, we found that Olig2 knockdown significantly increased tumor-free survival ( Figure 6A ). Olig2 knockdown was confirmed in tumors that were removed at early time points from presymptomatic mice ( Figure 6B ). Tumors that grew out from the Olig2 shRNA condition expressed Olig2 ( Figure 6C ), consistent with previous reports showing a significant role for Olig2 in human and mouse gliomas (Ligon et al., 2007; Mehta et al., 2011) . To further explore the relationship between Id1 and Olig2, primary mouse glioma cells were transiently transfected with Id1 siRNA, Olig2 siRNA or Control siRNA. Knockdown of Id1 did not affect Olig2 expression levels, and knockdown of Olig2 did not affect Id1 expression Error bars represent mean ± SD. See also Figure S4 . levels ( Figure S6C ), suggesting that neither gene directly represses the other in our model system. To begin to explore the role of Id1 and stemlike cells in human high-grade gliomas, we analyzed survival data from The Cancer Genome Atlas for each of the identified subtypes (Verhaak et al., 2010 ) based on Id1 expression for patients diagnosed with primary GBMs. Patients were subdivided into those with high Id1 expression (top 50%) and those with low Id1 expression (bottom 50%), compared to the unfiltered data set (Figures 7A-7D ). Within the Proneural subclass, patients with high Id1 expression had a median survival of 22.015 months, compared to patients with low Id1 expression, which had a median survival of 6.015 months ( Figure 7D ). No significant differences in survival were observed for the Classical, Mesenchymal and Neural subtypes when subdivided by Id1 expression ( Figures  7A-7C ). As the PDGF-driven murine model most closely mimics the Proneural subclass, this human data, while correlative, is consistent with our finding that low Id1 expression identifies a more aggressive tumor cell population in this subtype.
DISCUSSION
Self-renewal is the defining characteristic of both normal and cancer stem cells. It has been postulated that glioma cells with stem cell properties preferentially transplant disease and contribute disproportionately to tumor growth compared to other, more differentiated lineages. Our results argue against this stringent interpretation of the cancer stem cell hypothesis. Using a marker of normal adult neural stem cells, we identified glioma cells with high self-renewal capacity and compared their tumorigenic potential to that of low self-renewing lineages. We found that in PDGF-and KRAS-driven mouse glioma models, both cell populations were capable of transplanting disease, and cells with low self-renewal capacity were actually more tumorigenic. Thus, GICs cannot be exclusively identified by self-renewal or ''stemness.'' Using Id1 to Identify Stem-Like Glioma Cells Unlike the clearly defined, marker restricted lineages that exist in the hematopoietic system, stem and progenitor cells in the normal neurogenic niche and in brain tumors remain relatively ill-defined, complicating efforts to assign functional roles to these cell populations. While many studies use CD133 (Prominin 1) to identify glioma stem cells, CD133
-cells can also self-renew, suggesting that CD133 expression alone does not definitively identify glioma stem cells. High Id1 expression identifies type B cells in the normal neurogenic niche, and Id1 levels decrease gradually during lineage commitment (Nam and Benezra, 2009) . Reversion from an Id1 low to an Id1 high state is never observed, and we have therefore taken advantage of the Id1-VenusYFP knockin strain to isolate cells with high levels of Id1 within murine gliomas, and specifically identify the stemlike fraction. We define self-renewal capacity by the ability of cells to form multipotent tumorspheres of consistent progeny over serial passages when plated at clonal density in serum-free, adherentfree conditions. While definitive assays for self-renewal remain Error bars represent mean ± SD. See also Figure S5 .
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Self-Renewal Is Not Essential for Glioma Growth a matter of controversy, the ability of a glioma cell to form a tumorsphere under defined conditions has historically been used as an in vitro measure of self-renewal (Galli et al., 2004; Pastrana et al., 2011; Singh et al., 2003 Singh et al., , 2004 . A recent review by Pastrana et al. (2011) highlights a number of important considerations for the design and interpretation of sphereformation assays. Importantly, we sorted fluorescent cells directly from transgenic mice, eliminating issues related to antibody labeling and antigen presentation. We also plated cells in identical mitogenic conditions and used clonal densities to reduce the likelihood of aggregations. Further, we confirmed the multipotency and proliferation potential of our cell populations. Under these experimental conditions, Id1 high glioma cells were characterized by high self-renewal capacity, giving rise to tumorspheres with similar proportions of differentiated progeny over multiple passages, and thus maintaining multipotency. Id1 high cells also gave rise to heterogeneous tumors in vivo, fulfilling the criteria of glioma stem cells. By contrast, Id1 low glioma cells were characterized by low self-renewal capacity, generating tumorspheres with variable proportions of differentiated progeny. Undifferentiated Id1 low cells also expressed progenitor markers (including high levels of Olig2), and had the ability to generate heterogeneous tumors in vivo, making them more characteristic of multipotent progenitors. It has been hypothesized that, within tumors, Olig2 may represent a transition from a type B cell to a type C cell, although Olig2 is also expressed in more differentiated lineages (Ligon et al., 2007) (Figure 8 ). Although it is important to note that both populations were capable of transplanting disease, we were surprised to find that Id1 low cells generated tumors more quickly and with higher penetrance, indicating that self-renewal did not cosegregate with tumorigenic potential. Thus, the ability of a glioma cell to proliferate even while changing state (as seen in the Id1 low population) appears in this model system to be compatible with the ability to transplant disease efficiently.
Id1 high cells generated tumors with high levels of Olig2 expression, which is consistent with acquisition of Olig2 in the Id1 high population being a critical factor in its tumorigenic potential, and previous studies have indeed shown an essential role for Olig2 in gliomagenesis (Ligon et al., 2007) . While Id1 high cells
were capable of generating tumors with Olig2 expression, Id1 low cells never reverted to an Id1-expressing state. Therefore, the lineage hierarchy of the normal neurogenic niche, which proceeds unidirectionally from stem cell to progenitor cell, was also maintained in our murine glioma models. We found no evidence for interconversion from an Id1 low progenitor state to an Id1 high stem-like state, although such dedifferentiation has been reported in in vitro systems (Kondo and Raff, 2000) and may occur under other oncogenic conditions. Thus, Id1 low cells need not dedifferentiate and acquire Id1 expression in order to transplant disease. Our results also suggest that Id1 rather than from expanding progenitor pools that revert to an Id1 high state.
The Id1-expressing cells observed in tumors generated from Id1 low cells were derived exclusively from the host, and Fomchenko et al. (2011) recently found significant roles for recruited cells in PDGF-driven murine gliomas. These cells were shown to aid in disease transplantation and had the capacity to become independent of the initiating oncogene (Fomchenko et al., 2011) . We found that Id1 expression in the recruited population was not required for tumor growth, which was largely unaffected when Id1 low cells were transplanted into an Id1 À/À background.
Our Id1-knockout studies further support the idea that Id1 expression and self-renewal capacity is not essential for tumor growth. If tumors were dependent upon self-renewal for their growth potential, we would expect that knockout of Id1, which significantly impacted tumorsphere formation, would have a greater impact on overall survival than observed. Our Olig2-knockdown studies lend further support to the notion that progenitor cell lineages may make greater contributions to tumor growth in PDGF-driven gliomas.
ID Genes in High-Grade Gliomas
We have isolated glioma cells that express high levels of Id1, and find that they represent a highly self-renewing population of tumor cells, allowing us to probe the role of self-renewal in glioma growth, rather than the role of ID genes in glioma biology generally. However, multiple ID genes are upregulated in high-grade gliomas and implicated in glioma pathogenesis (Vandeputte et al., 2002) , and ID genes are known to have roles in tumor biology beyond self-renewal, including neoangiogenesis and regulation of cell-cycle (Perk et al., 2005) . Recently, Anido et al. (2010) isolated a CD44 high cell population from human patient derived glioma cells characterized by high levels of Id1 expression, TGF-ß-responsiveness and stem-like properties. These data are consistent with our results showing a role for Id1 in glioma cell self-renewal, and points to TGF-ß as a likely upstream regulator of Id1. While Id3 cosegregated with Id1 in our assays, Id2 and Id4 did not. It is likely that Id1/Id3 and Id2 and Id4 are expressed in different cell types and possess different functional roles depending on the specific tumorigenic context. While the effects of loss of Id1/3 on overall survival were modest in our model systems, it is possible that targeting additional Id proteins would yield a more dramatic effect, as this may impact both stemand progenitor-like cell populations. In fact, recent studies indicate that combined loss of Id1, Id2, and Id3 impacts glioma cell self-renewal as well as proliferation, leading to a significant delay in tumor progression (A.I., unpublished observations). Our finding that multiple lineages are capable of transplanting disease suggests that targeting a single cell population alone may not yield optimal therapeutic effects in these tumor subtypes.
Relevance to Human Disease
This work raises a number of questions regarding the origin and propagation of human high-grade gliomas. We know that multiple subclasses of human gliomas show a similar pattern of Id1 and Olig2 upregulation (Anido et al., 2010; Ligon et al., 2007; Vandeputte et al., 2002) and studies exploring at the effects of Olig2 knockdown in primary human glioma cells also show a significant delay in tumor development upon orthotopic transplantation , consistent with our mouse knockdown experiments. Further, data from TCGA suggest that, within the Proneural subclass, high Id1 expression is associated with a better survival outcome. As gliomas are highly heterogeneous tumors that can be classified into multiple subtypes, further work will be required to determine the role of self-renewing, stem-like cells in tumors generated with other mutations and amplifications as well as the relative response of these different cell populations to radiation and chemotherapy. It is possible that stem-like and progenitor-like cells have different contributions to tumorigenesis depending on the oncogenic context, and a careful analysis of these cell populations in additional tumor subtypes will be important for determining the optimal cell populations for therapeutic targeting. 
Immunostaining
The following primary antibodies were used: Id1 (Biocheck), Id3 (Biocheck), Olig2 (Millipore), MAP2 (Millipore), GFAP (Millipore), Tuj1 (mouse, Millipore), Tuj1 (rabbit, Covance), O4 (Millipore), Nestin (BD Biosciences), phosphorylated histone H3 (H3P; Sigma), Cleaved Caspase 3 (Cell Signaling Technology), CD133 (Miltenyi Biotech), and GFP (Abcam).
Flow Cytometry
Cells were sorted for VenusYFP expression with PI exclusion at our FACS facility using a MoFlo cell sorter (Cytomation).
In Vitro Tumorsphere Assays Tumors were papain digested (Worthington Biochemical), triturated and cells were plated for in vitro analysis in Neurocult Stem Cell Basal Media with Proliferation Supplements, 20 ng/ml EGF, 10 ng/ml FGF, and 2 mg/ml heparin (Stem Cell Technologies).
TCGA Kaplan-Meier Analysis
Id1 expression data were retrieved from the MSKCC cBio Cancer Genomics Portal (http://www.cbioportal.org/public-portal/). Patients were subdivided into high Id1 expression (top 50%) and low expression (bottom 50%) for analysis.
Statistics
Kaplan-Meier survival curves were generated with Prism software. All experiments were carried out in triplicate or greater. All p values are two-tailed and p values < 0.05 were considered significant. Data are shown as mean ± SD.
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